Bavarian Nordic — Juni 2021
-
Zealand Pharma: Opkøb og fortsat efterspørgsel skaber langsigtet potentiale
Zealand Pharma: Opkøb og fortsat efterspørgsel skaber langsigtet potentiale
Zealand Pharma skifter status til at blive et biofarmaceutisk selskab med salgbare produkter.
Dansk Aktionærforening (www.shareholders.dk)
-
ØU anbefaler Bava kortsigtet. Rent spec i at den er faldet for meget tilbage
-
Syge bevægelser i ZP - købt lige nu på 180 (flere) 2 sek efter 183 - nu 182.4. Vælger på ren mave at suplere her - ikke så meget snik snak
-
Mon ikke et aktietilbagekøbsprogram bliver en del af taktikken, når Zealand via egen drift likviditetsmæssigt er selvforsynende. Måske efter 2022?
-
ZP par
t 2- nu 188.. -
Tak exitnu
-
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
Company announcement – No. 35/ 2021 Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH ...
GlobeNewswire News Room (www.globenewswire.com)
-
havde lige rykket pænt ind på 180 - heldet følger de tossede ..og dem der agerer:)
-
tak;) og ja
-
ØU sendt spek tip ud kl 12:29
-
Syd fastholder Buy - ØU siger kortsigtet Buy
-
"Zealand is entitled to receive up to EUR 345 million in outstanding milestone payments. No milestone payments are due with the initiations of these Phase 2 studies. The agreement also carries high-single digit to low-double digit percentage royalties on global sales."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind